Cargando…

PPARγ inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner

Immune checkpoint blockade-based immunotherapy has become standard of care for multiple cancer types. However, the overall response rates among various cancer types still remain unsatisfactory. There is a pressing clinical need to identify combination therapies to improve efficacy of anticancer immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Bogang, Sun, Xiujie, Yuan, Bin, Ge, Fei, Gupta, Harshita B., Chiang, Huai-Chin, Li, Jingwei, Hu, Yanfen, Curiel, Tyler J., Li, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097912/ https://www.ncbi.nlm.nih.gov/pubmed/32226299 http://dx.doi.org/10.7150/ijbs.42966

Ejemplares similares

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation
por: Wu, Bogang, et al.
Publicado: (2020)

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice
por: Garcia, Myrna G., et al.
Publicado: (2022)

Estrogen receptor beta signaling in CD8(+) T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch
por: Yuan, Bin, et al.
Publicado: (2021)

Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy
por: Zhang, Deyi, et al.
Publicado: (2021)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

Direct AKT activation in tumor-infiltrating lymphocytes markedly increases interferon-γ (IFN-γ) for the regression of tumors resistant to PD-1 checkpoint blockade
por: Santinon, François, et al.
Publicado: (2022)

Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma
por: Xiong, Zhewen, et al.
Publicado: (2023)

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
por: Archilla-Ortega, Adrià, et al.
Publicado: (2022)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

4579 Distinct clinical and immunological responses to αPD-1, kαPD-L1 and αPD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences
por: Garcia, Myrna G, et al.
Publicado: (2020)

The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
por: Wong, Chun Wai, et al.
Publicado: (2023)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
por: Ou, Huilin, et al.
Publicado: (2022)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype
por: Hao, Xue, et al.
Publicado: (2020)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC)
por: Yan, Yihe, et al.
Publicado: (2021)

Zika virus oncolytic activity requires CD8(+) T cells and is boosted by immune checkpoint blockade
por: Nair, Sharmila, et al.
Publicado: (2021)

Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade
por: Sinha, Debottam, et al.
Publicado: (2022)

PPARγ in Neuroblastoma
por: Peri, Alessandro, et al.
Publicado: (2008)

Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade
por: Vackova, Julie, et al.
Publicado: (2020)

PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells
por: Gutting, Tobias, et al.
Publicado: (2021)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
por: Kulkarni, Ajit A., et al.
Publicado: (2012)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer
por: Nada, Mohanad H., et al.
Publicado: (2021)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Koyama, Shohei, et al.
Publicado: (2016)

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
por: Zhang, Fei, et al.
Publicado: (2017)

Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy
por: Ilett, Elizabeth, et al.
Publicado: (2016)

RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade
por: Heidegger, Simon, et al.
Publicado: (2019)

Arachidonic Acid Metabolism Controls Macrophage Alternative Activation Through Regulating Oxidative Phosphorylation in PPARγ Dependent Manner
por: Xu, Miao, et al.
Publicado: (2021)

PPARγ inhibited tumor immune escape by inducing PD‐L1 autophagic degradation
por: Gou, Qian, et al.
Publicado: (2023)

Muscle Injuries Induce a Prostacyclin‐PPARγ/PGC1a‐FAO Spike That Boosts Regeneration
por: Luo, Lanfang, et al.
Publicado: (2023)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dij0d9tdveo0hksnk8b3q3q1b5